HCC
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
HCC
Jul 24, 2024, 08:58 |
Opinion
Hepatic decompensation and mortality in HCC treated with atezo-beva
Erman Akkus, Medical Oncologist at Ankara University, shared on X about an article titled "Hepatic…
Jul 16, 2024, 11:37 |
Blog
Ghassan Abou-Alfa: What is the most common etiology of HCC in the Pacific Islands and Atolls?
Ghassan Abou-Alfa, Associate Attending at Memorial Sloan Kettering Cancer Center, shared on X: "What is…
Jul 8, 2024, 18:50 |
Blog
Tumor Board Tuesday on Durva + TACE for HCC
Tumor Board Tuesday published the following post on X: “Did you know that there are…
Jul 8, 2024, 03:46 |
Blog
Erman Akkus: The predictors of aggressive recurrence of HCC after resection
Erman Akkus, Medical Oncology Fellow at Ankara University Faculty of Medicine, shared on X: "What…
Jun 27, 2024, 02:53 |
Blog
Tanja Obradovic: Tempest Therapeutics just announced very good results from ongoing global clinical study with Amezalpat
Tanja Obradovic shared on LinkedIn: . “Are we to expect completely new mechanism of action…
Jun 15, 2024, 15:17 |
Blog
Mairead G McNamara: Great discussion and critique at liver clinical stream at UKOF24
Mairead G McNamara. Senior Lecturer/Honorary Consultant in Medical Oncology at the University of Manchester, shared…
Jun 9, 2024, 10:17 |
Insight
Arndt Vogel shares news from EASL 2O24
Arndt Vogel shared the following posts from EASL 2O24 on X: "Liver transplantation following HCC…
Jun 6, 2024, 09:05 |
Blog
ASCO24 trials summarized by Arndt Vogel
Arndt Vogel shared on X/Twitter: "NIVO + IPI vs LEN (90%) or SORA as 1st line…
May 23, 2024, 11:18 |
Blog
Sarabjot Pabla: Our latest molecular tumor board with a case of recurrent HCC
Sarabjot Pabla, Head of Clinical and Research Bioinformatics at OmniSeq, shared a post on LinkedIn:…
May 17, 2024, 16:56 |
Insight
Piotr Wysocki: Liver resection vs nonsurgical treatments in patients with early multinodular hepatocellular cancer
Piotr Wysocki recently posted on LinkedIn: "Current Barcelona Clinic Liver Cancer guidelines do not support…
May 15, 2024, 14:07 |
Blog
Rasha Aboelhassan: I'm honoured to be a part of the HCC committee in Nasser Institute
Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared a post on LinkedIn: “Management of…
May 7, 2024, 15:35 |
Insight
Arndt Vogel: Excellent summary on precision medicine in HCC
Arndt Vogel shared on X: "Precision treatment in advanced HCC. Excellent summary on precision medicine…
Apr 13, 2024, 14:18 |
Insight
Jonathan Cohen discusses hepatocellular carcinoma at the annual meeting of the Israeli Oncology Society
Jonathan Cohen, Director of Clinical Research at Sharett Institute of Oncology of Hadassah Medical Center,…
Apr 12, 2024, 17:36 |
Insight
Mark Yarchoan: Multicenter P1/2 trial of a personalized neoantigen vaccine + anti-PD1 in 2L HCC presented at AACR24
Mark Yarchoan, Associate Professor at Johns Hopkins Hospital, shared on X: "Multicenter P1/2 trial of…
Apr 10, 2024, 09:52 |
Insight
David Pinato: Immunotherapy might become a novel standard of care in intermediate-stage HCC
David Pinato, Director of Developmental Cancer Therapeutics at Imperial College London, shared on LinkedIn: "Immunotherapy…
Mar 28, 2024, 02:23 |
Drugs
Angela Lamarca: Great news for patients diagnosed with Biliary Malignancies and HCC in Spain
Angela Lamarca, Consultant in Medical Oncology at Jiménez Díaz Foundation University Hospital, shared a post…
Mar 27, 2024, 13:02 |
Blog
Erman Akkus: ESMO-2023, hepatobiliary and pancreatic cancers
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "ESMO-2023, hepatobiliary and pancreatic…
Mar 2, 2024, 12:40 |
Blog
David James Pinato: Immunotherapy is truly changing the way we treat HCC
David James Pinato, Director of Developmental Cancer Therapeutics, Clinical Senior Lecturer and Consultant Medical Oncologist…
Feb 21, 2024, 18:13 |
Insight
Erman Akkus: Tremelimumab plus durvalumab (STRIDE) in HCC-HIMALAYA update
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "Tremelimumab plus durvalumab (STRIDE)…
Feb 12, 2024, 17:11 |
Blog
Laura Dawson: The SBRT debate was a wonderful way to end the HCC-LIVE Conference
Laura Dawson, Professor & Chair Department Radiation Oncology at the University of Toronto, shared the…
Nov 1, 2023, 14:45 |
Blog
Translational Research in Oncology announced the first patient was randomized in the REPLACE (TRIO041) trial
Translational Research in Oncology shared on their LinkedIn page: ''TRIO is happy to announce that…
Aug 25, 2023, 18:25 |
Insight
Arndt Vogel: Immune Checkpoint Inhibitors for Child-Pugh B HCC: comprehensive summary of 22 studies with 699 patients.
Quoting Arndt Vogel on X/Twitter: "Hot off the press: Immune Checkpoint Inhibitors for CP B…
Jun 12, 2023, 03:13 |
Drugs
The third country worldwide to approve this medication for HCC in combination with Durvalumab - Prof.Humaid Al-Shamsi
Last night in Dubai , in collaboration with AstraZeneca we successfully launched tremelimumab for the treatment of…
All:
23
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube